Figure 3
PFS for alternate KI. (A) PFS from start of alternate KI (ibrutinib → idelalisib, idelalisib→ ibrutinib). (B) PFS from start of alternate KI stratified by reason for discontinuation (CLL progression vs KI intolerance).
PFS for alternate KI. (A) PFS from start of alternate KI (ibrutinib → idelalisib, idelalisib→ ibrutinib). (B) PFS from start of alternate KI stratified by reason for discontinuation (CLL progression vs KI intolerance).
